Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299034 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4EHTR2AMAPTMEN1 | |
| SCHEMBL28592383 | 1.00 | ALDH1A1 (0.49) | ALDH1A1KDM4EHTR2AMAPTMEN1 | |
| SCHEMBL6269049 | 0.79 | HTR2A (0.59) | ALDH1A1KDM4EHTR2AMAPTMEN1 | |
| SCHEMBL9156352 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL6807174 | 0.76 | CA2 (0.44) | ALDH1A1KMT2AEPHX1CA12CA1 | |
| SCHEMBL6807193 | 0.76 | CA2 (0.44) | ALDH1A1KMT2AEPHX1CA12CA1 | |
| SCHEMBL6808021 | 0.76 | CA2 (0.44) | ALDH1A1KMT2AEPHX1CA12CA1 | |
| SCHEMBL14384661 | 0.76 | ALDH1A1 (0.57) | ALDH1A1KDM4EHTR2AMAPTMEN1 | |
| SCHEMBL18256235 | 0.76 | ALDH1A1 (0.57) | ALDH1A1KDM4EHTR2AMAPTMEN1 | |
| SCHEMBL14384138 | 0.76 | ALDH1A1 (0.57) | ALDH1A1KDM4EHTR2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0926951-B1 | TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | claimed |
| EP-0926951-A4 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2001-08-08 | — | — | EP | claimed |
| EP-0926951-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998006261-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-19 | — | — | WO | claimed |
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2021127517-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| US-20200197368-A1 | METHODS OF IMPROVING CANCER CHEMOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-25 | — | — | US | disclosed |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| US-20080249055-A1 | Use of Seh Inhibitors as Analgesics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-09 | — | — | US | disclosed |
| US-20050222252-A1 | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-06 | — | — | US | disclosed |
| EP-0926951-B1 | TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-0926951-A4 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | UNIV CALIFORNIA (US) | 2001-08-08 | — | — | EP | disclosed |
| US-6174695-B1 | DETERMINING INTRACELLULAR CHANGE IN CALCIUM LEVELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-01-16 | — | — | US | disclosed |
| US-5955496-A | TREATING ADULT RESPIRATORY DISTRESS SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0926951-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998006261-A1 | METHODS OF TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249055-A1 | Use of Seh Inhibitors as Analgesics | EPHX1, FAAH, EPHX2 | ALDH1A1 526/4885KDM4E 3401/4885HTR2A 2154/4885 |
| US-20200197368-A1 | METHODS OF IMPROVING CANCER CHEMOTHERAPY | ALOX5, EPHX1, ALOX12 | ALDH1A1 107/4885KDM4E 2392/4885HTR2A 1254/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | ALDH1A1 1578/4885KDM4E 3635/4885HTR2A 3044/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | ALDH1A1 187/4885KDM4E 1449/4885HTR2A 397/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | ALDH1A1 182/4885KDM4E 2385/4885HTR2A 3132/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | ALDH1A1 187/4885KDM4E 1449/4885HTR2A 397/4885 |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | EPHX1, SERPINB1, PTGES | ALDH1A1 375/4885KDM4E 2787/4885HTR2A 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.